Resell, M., Rabben, H.-L., Sharma, A., Hagen, L., Hoang, L., Skogaker, N. T., Aarvik, A., Bjåstad, E. K., Svensson, M. K., Amrutkar, M., Verbeke, C. S., Batra, S. K., Qvigstad, G., Wang, T. C., Rustgi, A., Chen, D., & Zhao, C.-M. (2025). Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma. Scientific Data, 12(1). https://doi.org/10.1038/s41597-025-04522-x

Kondo, Y., Ohashi, S., Katada, C., Nakai, Y., Yamamoto, Y., Tamaoki, M., Kikuchi, O., Yamada, A., Hirohashi, K., Mitani, Y., Kataoka, S., Saito, T., Vu, T. H. N., Kondo, T., Uneno, Y., Sunami, T., Yokoyama, A., Matsubara, J., Matsuda, T., … Muto, M. (2025). Aldh2 and the tumor suppressor Trp53 play important roles in alcohol-induced squamous field cancerization. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02210-y

Park, J., Karnati, H., Rustgi, S. D., Hur, C., Kong, X.-F., & Kastrinos, F. (2025). Impact of population screening for Lynch syndrome insights from the All of Us data. Nature Communications, 16(1). https://doi.org/10.1038/s41467-024-52562-5

Sommerhalder, D., Demel, K., Noel, M. S., Emamekhoo, H., Peguero, J., Balaraman, R., Moy, R. H., Scheuber, A., Haas, J., Chabas, D., Kumar, P., Daigle, S. R., Dasen, S., Zhang, X., Gutierrez, M., Sharma, S., & Hussain, A. (2024). 682 Ongoing phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical safety update and renal cell carcinoma (RCC) efficacy analysis. Regular and Young Investigator Award Abstracts, A782–A783. https://doi.org/10.1136/jitc-2024-sitc2024.0682

Daigle, S. R., Elliott, G., Boiko, S., Sommerhalder, D., Noel, M. S., Sharma, S., Balaraman, R., Gutierrez, M., Demel, K., Moy, R. H., Ciccone, D., Zhang, X., Scheuber, A., & Kumar, P. (2024). 83 Tumor immune microenvironment characterization from pre- and post-dose tumors collected from a phase 1/2 study of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Regular and Young Investigator Award Abstracts, A91–A91. https://doi.org/10.1136/jitc-2024-sitc2024.0083

Shafighi, S., Geras, A., Jurzysta, B., Sahaf Naeini, A., Filipiuk, I., Ra̧czkowska, A., Toosi, H., Koperski, Ł., Thrane, K., Engblom, C., Mold, J. E., Chen, X., Hartman, J., Nowis, D., Carbone, A., Lagergren, J., & Szczurek, E. (2024). Integrative spatial and genomic analysis of tumor heterogeneity with Tumoroscope. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-53374-3

Chen, L. N., Keating, C., Leb, J., Saqi, A., & Shu, C. A. (2024). Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer. Respiratory Medicine Case Reports, 51, 102091. https://doi.org/10.1016/j.rmcr.2024.102091

Luthria, K., Shah, P., Caldwell, B., Melms, J. C., Abuzaid, S., Jakubikova, V., Brodtman, D. Z., Bose, S., Amin, A. D., Ho, P., Biermann, J., Tagore, S., Ingham, M., Schwartz, G. K., & Izar, B. (2024). Single-cell profiling of sarcomas from archival tissue reveals programs associated with resistance to immune checkpoint blockade. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-2976

Hua, X., Zhou, H., Wu, H.-C., Furnari, J., Kotidis, C. P., Rabadan, R., Genkinger, J. M., Bruce, J. N., Canoll, P., Santella, R. M., & Zhang, Z. (2024). Tumor detection by analysis of both symmetric- and hemi-methylation of plasma cell-free DNA. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-50471-1

Kabeer, F., Tran, H., Andronescu, M., Singh, G., Lee, H., Salehi, S., Wang, B., Biele, J., Brimhall, J., Gee, D., Cerda, V., O’Flanagan, C., Algara, T., Kono, T., Beatty, S., Zaikova, E., Lai, D., Lee, E., … Moore, R. (2024). Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers. Genome Biology, 25(1). https://doi.org/10.1186/s13059-024-03318-3

Zaidi, S., Park, J., Chan, J. M., Roudier, M. P., Zhao, J. L., Gopalan, A., Wadosky, K. M., Patel, R. A., Sayar, E., Karthaus, W. R., Kates, D. H., Chaudhary, O., Xu, T., Masilionis, I., Mazutis, L., Chaligné, R., Obradovic, A., Linkov, I., Barlas, A., … Sawyers, C. L. (2024). Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies. Proceedings of the National Academy of Sciences, 121(28). https://doi.org/10.1073/pnas.2322203121

Faber, E. B., Baca, Y., Xiu, J., Walker, P., Manji, G., Gholami, S., Saeed, A., Prakash, A., Botta, G. P., Sohal, D., Lenz, H. J., Shields, A. F., Nabhan, C., El-Deiry, W., Seeber, A., Chiu, V., Hwang, J., & Lou, E. (2024). Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status. ESMO Gastrointestinal Oncology, 4, 100042. https://doi.org/10.1016/j.esmogo.2024.100042

Karloski, E., Dudley, B., Diergaarde, B., Blanco, A., Everett, J. N., Levinson, E., Rangarajan, T., Stanich, P. P., Childers, K., Brown, S., Drogan, C., Cavestro, G. M., Gordon, K., Singh, A., Simeone, D. M., Reich, H., Kastrinos, F., Zakalik, D., Hampel, H., … Brand, R. E. (2024). The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Cancer. Portico. https://doi.org/10.1002/cncr.35383

Ali, A. M., & Raza, A. (2024). scRNAseq and High-Throughput Spatial Analysis of Tumor and Normal Microenvironment in Solid Tumors Reveal a Possible Origin of Circulating Tumor Hybrid Cells. Cancers, 16(7), 1444. https://doi.org/10.3390/cancers16071444

Zogopoulos, G., Haimi, I., Sanoba, S. A., Everett, J. N., Wang, Y., Katona, B. W., Farrell, J. J., Grossberg, A. J., Paiella, S., Klute, K. A., Bi, Y., Wallace, M. B., Kwon, R. S., Stoffel, E. M., Wadlow, R. C., Sussman, D. A., Merchant, N. B., Permuth, J. B., Golan, T., … __. (2024). The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Journal of the National Comprehensive Cancer Network, 22(3), 158–166. https://doi.org/10.6004/jnccn.2023.7097

Atkins, M. B., Jegede, O. A., Haas, N. B., Mcdermott, D. F., Bilen, M. A., Stein, M., Sosman, J., Alter, R., Plimack, E. R., Ornstein, M. C., Hurwitz, M., Peace, D. J., Einstein, D., Catalano, P. J., Hammers, H., & Regan, M. M. (2024). Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for ImmunoTherapy of Cancer, 12(4), e008293. https://doi.org/10.1136/jitc-2023-008293

Fojo, T., LaRose, M., & Bates, S. E. (2024). The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype. The Oncologist, 29(4), 275–277. https://doi.org/10.1093/oncolo/oyae042

Ben-Ami, R., Wang, Q.-L., Zhang, J., Supplee, J. G., Fahrmann, J. F., Lehmann-Werman, R., Brais, L. K., Nowak, J., Yuan, C., Loftus, M., Babic, A., Irajizad, E., Davidi, T., Zick, A., Hubert, A., Neiman, D., Piyanzin, S., Gal-Rosenberg, O., Horn, A., … Wolpin, B. M. (2023). Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut, gutjnl-2023-331074. https://doi.org/10.1136/gutjnl-2023-331074

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Bellair, M., Amaral, E., Ouren, M., Roark, C., Kim, J., O’Connor, A., Soriano, A., Schindler, M. L., Wapner, R. J., Stone, J. L., Tavella, N., Merriam, A., Perley, L., Breman, A. M., & Beaudet, A. L. (2024). Noninvasive single‐cell‐based prenatal genetic testing: A proof of concept clinical study. Prenatal Diagnosis, 44(3), 304–316. Portico. https://doi.org/10.1002/pd.6529

Galbraith, K., Vasudevaraja, V., Serrano, J., Shen, G., Tran, I., Abdallat, N., Wen, M., Patel, S., Movahed-Ezazi, M., Faustin, A., Spino-Keeton, M., Roberts, L. G., Maloku, E., Drexler, S. A., Liechty, B. L., Pisapia, D., Krasnozhen-Ratush, O., Rosenblum, M., Shroff, S., … Snuderl, M. (2023). Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad076

Diaz, M., Chudsky, S., Pentsova, E., & Miller, A. M. (2024). Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors. Translational Oncology, 41, 101881. https://doi.org/10.1016/j.tranon.2024.101881

Levy, B., Kanagal‐Shamanna, R., Sahajpal, N. S., Neveling, K., Rack, K., Dewaele, B., Olde Weghuis, D., Stevens‐Kroef, M., Puiggros, A., Mallo, M., Clifford, B., Mantere, T., Hoischen, A., Espinet, B., Kolhe, R., Solé, F., Raca, G., & Smith, A. C. (2024). A framework for the clinical implementation of optical genome mapping in hematologic malignancies. American Journal of Hematology, 99(4), 642–661. Portico. https://doi.org/10.1002/ajh.27175

Zhuo, X., Aggarwal, V., & Liao, J. (2024). P641: Application of AlphaMissense prediction to pathogenicity classification of missense variants from clinical exome sequencing. Genetics in Medicine Open, 2, 101547. https://doi.org/10.1016/j.gimo.2024.101547

Chen, X., Li, Y., Zhu, F., Xu, X., Estrella, B., Pazos, M. A., McGuire, J. T., Karagiannis, D., Sahu, V., Mustafokulov, M., Scuoppo, C., Sánchez-Rivera, F. J., Soto-Feliciano, Y. M., Pasqualucci, L., Ciccia, A., Amengual, J. E., & Lu, C. (2023). Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39990-5

Oxnard, G. R., Chen, R., Pharr, J. C., Koeller, D. R., Bertram, A. A., Dahlberg, S. E., Rainville, I., Shane-Carson, K., Taylor, K. A., Sable-Hunt, A., Sholl, L. M., Teerlink, C. C., Thomas, A., Cannon-Albright, L. A., Fay, A. P., Ashton-Prolla, P., Yang, H., Salvatore, M. M., Addario, B. J., … Garber, J. E. (2023). Germline EGFR Mutations and Familial Lung Cancer. Journal of Clinical Oncology, 41(34), 5274–5284. https://doi.org/10.1200/jco.23.01372

Park, J., Lim, F., Prest, M., Ferris, J. S., Aziz, Z., Agyekum, A., Wagner, S., Gulati, R., & Hur, C. (2023). Quantifying the potential benefits of early detection for pancreatic cancer through a counterfactual simulation modeling analysis. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-46751-3

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 424–424. https://doi.org/10.1182/blood-2023-186822

Chapman, O. S., Luebeck, J., Sridhar, S., Wong, I. T.-L., Dixit, D., Wang, S., Prasad, G., Rajkumar, U., Pagadala, M. S., Larson, J. D., He, B. J., Hung, K. L., Lange, J. T., Dehkordi, S. R., Chandran, S., Adam, M., Morgan, L., Wani, S., Tiwari, A., … Chavez, L. (2023). Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma. Nature Genetics, 55(12), 2189–2199. https://doi.org/10.1038/s41588-023-01551-3

Rosenberg, S. M., McCue, S., He, J., Lafky, J. M., Carey, L. A., Galanis, E., Leonard, J. P., Meyerhardt, J., Ng, K., Schwartz, G. K., Stock, W., Paskett, E. D., Partridge, A. H., & George, S. (2023). Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer, 130(5), 750–769. Portico. https://doi.org/10.1002/cncr.35078

Xu, J. J., Chen, Y., Pantazi, J., Fernando, S., Alija, B., Sudunagunta, V., Bhagat, G., & Viny, A. D. (2023). Synergy of Stag2-Cohesin Loss Results in Expansion of Npm1c-Mutant Hematopoietic Stem and Progenitor Cells. Blood, 142(Supplement 1), 954–954. https://doi.org/10.1182/blood-2023-190627

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 4316–4316. https://doi.org/10.1182/blood-2023-186376

Leighl, N., Cho, B. C., Hiret, S., Han, J.-Y., Lee, K. H., Llacer Perez, C., Krebs, M. G., De Braud, F., Haura, E., Sanborn, R. E., Yang, J. C.-H., Shu, C. A., Goto, K., Nishio, M., Zhao, J., Wang, Z., Tomasini, P., Felip, E., Goldman, J. W., … Spira, A. I. (2023). OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. Journal of Thoracic Oncology, 18(11), S93–S94. https://doi.org/10.1016/j.jtho.2023.09.105

Mckean, M., Chmielowski, B., Butler, M. O., Carvajal, R., Rodon, J., Carlino, M., Kim, K. B., Wise-draper, T., Khan, S., Salama, A. K. S., Moser, J., Reeves, J., Wilner, K. D., Maurer, M., Abed, M., Mitchell, B., Beaupre, D., & Orloff, M. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology, 34, S651. https://doi.org/10.1016/j.annonc.2023.09.2215

Levy, B., Baughn, L. B., Akkari, Y., Chartrand, S., LaBarge, B., Claxton, D., Lennon, P. A., Cujar, C., Kolhe, R., Kroeger, K., Pitel, B., Sahajpal, N., Sathanoori, M., Vlad, G., Zhang, L., Fang, M., Kanagal-Shamanna, R., & Broach, J. R. (2023). Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Advances, 7(7), 1297–1307. https://doi.org/10.1182/bloodadvances.2022007583

Lee, T. D., Aisner, D. L., David, M. P., Eno, C. C., Gagan, J., Gocke, C. D., Guseva, N. V., Haley, L., Jajosky, A. N., Jones, D., Mansukhani, M. M., Mroz, P., Murray, S. S., Newsom, K. J., Paulson, V., Roy, S., Rushton, C., Segal, J. P., Senaratne, T. N., … Kim, A. S. (2023). Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances, 7(16), 4599–4607. https://doi.org/10.1182/bloodadvances.2023010149

Bridge, J. A., Halling, K. C., Moncur, J. T., Souers, R. J., Hameed, M. R., Fernandes, H., Roy, A., Surrey, L., Tafe, L. J., Vasalos, P., & Lopez-Terrada, D. H. (2023). RNA Sequencing for Solid Tumor Fusion Gene Detection: Proficiency Testing Practice and Performance Comparison. Archives of Pathology & Laboratory Medicine, 148(5), 538–544. https://doi.org/10.5858/arpa.2023-0047-cp

Klein, H.-U. (2023). demuxmix: demultiplexing oligonucleotide-barcoded single-cell RNA sequencing data with regression mixture models. Bioinformatics, 39(8). https://doi.org/10.1093/bioinformatics/btad481

Manji, G. A., Labadie, B. W., Lee, S. M., Pellicciotta, I., Ge, L., Sta Ana, S., Sender, N., Ross, I., Wong, W., & Raufi, A. G. (2023). MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies. JCO Global Oncology, 9(Supplement_1), 45–45. https://doi.org/10.1200/go.2023.9.supplement_1.45

Awah, C. U., Glemaud, Y., Levine, F., Yang, K., Ansary, A., Dong, F., Ash, L., Zhang, J., & Ogunwobi, O. O. (2023). Destabilized 3’UTR elements therapeutically degrade ERBB2 mRNA in drug-resistant ERBB2+ cancer models. Frontiers in Genetics, 14. https://doi.org/10.3389/fgene.2023.1184600

Tshering, L. F., Luo, F., Russ, S., Szenk, M., Rubel, D., Tutuska, K., Rail, J. G., Balázsi, G., Shen, M. M., & Talos, F. (2023). Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Developmental Cell, 58(12), 1071-1086.e8. https://doi.org/10.1016/j.devcel.2023.04.010

Okolo, O., Yu, V., Flashner, S., Martin, C., Nakagawa, H., Lin, D. T., Puram, S. V., & Parikh, A. S. (2023). Protocol for tumor dissociation and fluorescence-activated cell sorting of human head and neck cancers. STAR Protocols, 4(2), 102294. https://doi.org/10.1016/j.xpro.2023.102294

Graff, S. L., Bansal, R., Adeyelu, T., Elliott, A., Bustos, M., Rodriguez, E., Accordino, M., Meisel, J., Gatti-Mays, M., Hsu, E., Lathrop, K. I., Kaklamani, V., Oberley, M., Sledge, G., & Sammons, S. (2023). 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer. ESMO Open, 8(1), 101404. https://doi.org/10.1016/j.esmoop.2023.101404

Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A. T., Vokes, N. I., Sakhi, M., Kamesan, V., Rizvi, H., Ricciuti, B., Forde, P. M., Anagnostou, V., Riess, J. W., … Gainor, J. F. (2023). Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics, 55(5), 807–819. https://doi.org/10.1038/s41588-023-01355-5

Spillmann, R. C., Tan, Q. K.-G., Reuter, C., Schoch, K., Kohler, J., Bonner, D., Zastrow, D., Alkelai, A., Baugh, E., Cope, H., Marwaha, S., Wheeler, M. T., Bernstein, J. A., Shashi, V., Acosta, M. T., Adam, M., Adams, D. R., Alvey, J., Amendola, L., … Zuchner, S. (2023). A concurrent dual analysis of genomic data augments diagnoses: Experiences of 2 clinical sites in the Undiagnosed Diseases Network. Genetics in Medicine, 25(4), 100353. https://doi.org/10.1016/j.gim.2022.12.001

Oren, D., Moeller, C. M., Rubinstein, G., Lotan, D., DeFilippis, E. M., Mehlman, Y., Raja, A., Slomovich, S., Clerkin, K., Fried, J., Raikhelkar, J., Lin, E., Oh, K., Lee, S., Topkara, V., Latif, F., Majure, D., Sayer, G., & Uriel, N. (2023). (758) Evaluation of Donor Derived Cell-Free DNA in ABO Mismatched Heart Transplant Patients. The Journal of Heart and Lung Transplantation, 42(4), S334. https://doi.org/10.1016/j.healun.2023.02.772

Fulop, D. J., Zylberberg, H. M., Wu, Y. L., Aronson, A., Labiner, A. J., Wisnivesky, J., Cohen, D. J., Sigel, K. M., & Lucas, A. L. (2023). Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. JAMA Network Open, 6(3), e234254. https://doi.org/10.1001/jamanetworkopen.2023.4254

Santhanam, B., Oikonomou, P., & Tavazoie, S. (2023). Systematic assessment of prognostic molecular features across cancers. Cell Genomics, 3(3), 100262. https://doi.org/10.1016/j.xgen.2023.100262

Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C. W., Karan, C., Realubit, R., Pampou, S., Kim, J. Y., Afari, S. N., Mukhammadov, T., Zanella, L., Corey, E., … Abate-Shen, C. (2022). OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery, 13(2), 386–409. https://doi.org/10.1158/2159-8290.cd-22-0342

de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., Lee, S. Y., Bryl, M., Zer, A., Erman, M., Timcheva, C., Raja, R., Naicker, K., Scheuring, U., Walker, J., … Mok, T. (2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106–119. https://doi.org/10.1016/j.jtho.2022.09.223